Michael P. Wheatcroft
Suite 401, 55 Flemington Road
North Melbourne, VIC 3051, Australia
North Melbourne, VIC 3051, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Influence of immune checkpoint inhibitor target and timing on combination treatment with antibody-based β-emitting targeted radionuclide therapy across tumor immunogenicity profiles.
Journal: Frontiers in immunology
Published: May 05, 2026
Predicting tumour and organ dose in α-radiopharmaceutical therapy: a 89Zr-based dosimetric approach for 225Ac.
Journal: European journal of nuclear medicine and molecular imaging
Published: April 02, 2026
Synthesis and Evaluation of D8W, an Octadentate Desferrioxamine Analogue with Enhanced Water Solubility Designed for 89Zr-ImmunoPET Imaging.
Journal: Molecular pharmaceutics
Published: January 26, 2026
Development of a Novel Engineered Antibody Format for PSMA-Targeted Radionuclide Therapy.
Journal: Molecular pharmaceutics
Published: May 22, 2025
Preclinical evaluation and automated synthesis of [89Zr]ZrDFOSquaramide-girentuximab for diagnostic imaging of carbonic anhydrase IX positive tumours.
Journal: EJNMMI radiopharmacy and chemistry
Published: September 17, 2024
DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: August 26, 2024
[89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial.
Journal: The Lancet. Oncology
Published: May 24, 2024
A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements.
Journal: Chemical science
Published: April 30, 2024
Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma.
Journal: Theranostics
Published: April 03, 2024
Automated synthesis of [89Zr]ZrCl4, [89Zr]ZrDFOSquaramide-bisPh(PSMA) and [89Zr]ZrDFOSquaramide-TATE.
Journal: EJNMMI radiopharmacy and chemistry
Published: March 24, 2024
Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: March 15, 2022
Imaging Somatostatin Positive Tumors with Tyr3-Octreotate/Octreotide Conjugated to Desferrioxamine B Squaramide Radiolabeled with either Zirconium-89 or Gallium-68.
Journal: Bioconjugate chemistry
Published: March 31, 2021
Last Updated: 09/26/2026